Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Type/Product Area

Terms/Details (Date)


Abnova Corp.*
(Taiwan)

Axela Biosensors Inc.* (Canada)

Deal to co-develop reagents and biomarker panels for use on Axela's dotLab System

Abnova will optimize a series of monoclonal antibodies in the effort; terms of the deal were not disclosed (9/27)

AdnaGen AG*
(Germany)

Innogenetics NV (Belgium; Euronext:INNX)

Innogenetics got an option to get rights to technology for isolating fetal red blood cells circulating in maternal blood

The goal is to develop a diagnostic product for prenatal testing; the monoclonal antibody-based technology is designed to be specific and selective; terms of the deal were not disclosed (9/19)

Affimed
Therapeutics
AG*
(Germany)

XOMA Ltd. (XOMA)

They entered a cross-license and collaboration agreement covering antibody-related technologies

XOMA gets rights to technology for antibody discovery, as well as two customized libraries; Affimed gets research rights to XOMA's Bacterial Cell Expression technology; terms were not disclosed (10/2)

Affymetrix
Inc.
(AFFX)

NimbleGen Systems Inc.*

NimbleGen got rights to nucleic acid microarrays and related products and services in the research field

Terms of the nonexclusive deal were not disclosed; the deal covers manufacturing, use and sales (10/6)

Algeta ASA*
(Norway)

Affibody AB* (Sweden)

Collaboration to develop targeted radiotherapeutics for cancer indications

Algeta's technology for attaching thorium-227 to peptides and proteins will be used with Affibody's molecules that target tumor cells overexpressing HER2; terms of the deal were not disclosed (8/16)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Quark Biotech Inc.*

Quark got rights to develop and market RNAi therapeutics targeting the p53 and RTP801 genes, for certain diseases

Alnylam is entitled to up-front and annual payments, as well as potential milestone and royalty payments; also, Quark agreed to not support opposition to Kreutzer- Limmer patents granted in Europe (9/26)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Biogen Idec Inc. (BIIB)

Deal to discover and develop RNAi therapeutics for treating progressive multifocal leukoencephalopathy

Alnylam gets $5M up front, and could earn more than $51M in milestone payments, as well as royalties on sales; Biogen will fund research (9/20)

Alnylam
Pharmaceuticals
Inc.
(ALNY)

Calando Pharmaceuticals (majority owned by Arrowhead Research Corp.; ARWR)

Calando got rights to develop an RNAi drug that uses a synthetic siRNA with its delivery technology, directed at a cancer target

Calando also has an option to acquire a license for a second target gene; Alnylam is entitled to up-front and annual payments, along with milestone and royalty payments on resulting products (8/17)

AnorMED
Inc.
(Canada;
ANOR)

Poniard Pharmaceuticals Inc. (PARD; formerly NeoRx Corp.)

They broadened license agreement covering the cancer agent picoplatin

Poniard gained exclusive worldwide rights under the deal, which also eliminated payment of development milestones and reduced the rate of royalties paid to AnorMED (9/19)

Aphton Corp.
(PK:APHTQ)

Receptor
BioLogix Inc.*

Receptor acquired the cancer vaccine Insegia (G17DT), which failed to demonstrate survival benefits in Phase III trials

The product was acquired in a bankruptcy sale; Receptor believes further development is warranted (7/31)

A.P. Pharma
Inc.
(APPA)

RHEI
Pharmaceuticals
Inc.*

RHEI got rights in greater China to APF530, a product in Phase III for preventing chemotherapy-induced nausea and vomiting

A.P. gets an up-front fee, and is eligible to receive milestone payments; it would get double-digit royalties on sales (10/2)

Aradigm Corp. (ARDM)

Zogenix Inc.*

Zogenix purchased Aradigm's Intraject subcutaneous delivery technology and related assets

Aradigm gets $4M up front from newly formed Zogenix, and is eligible to receive a milestone payment and royalties on resulting sales (8/28)

Arbor Vita
Corp.*

NoNO Inc.* (Canada)

Deal to develop and commercialize drugs for treating stroke

The effort pairs Arbor Vita's PDZ-based discovery platform with NoNO's expertise in neurological disorders; terms were not disclosed (10/16)

Archemix
Corp.*

Nuvelo Inc. (NUVO)

They entered a new deal, replacing previous 50-50 collaboration, to develop short-acting aptamers for cardiovascular indications

Nuvelo will pay Archemix $4M up front, provide at least $5.25M in research funding over three years and may invest up to $10M upon an Archemix IPO; Archemix also could get $35M in milestone payments per compound, and royalties on sales; it also has a profit-sharing option (8/1)

Ariad
Pharmaceuticals
Inc.
(ARIA)

Bellicum Pharmaceuticals Inc.*

Bellicum got nonexclusive rights to use Argent cell- signaling regulation technology in cancer drug development

Products in this deal will use Ariad's dimerizer drug, AP1903; Ariad gets an equity stake in Bellicum, and is eligible to receive milestone payments (10/11)

BaroFold Inc.*

Genentech Inc. (NYSE:DNA)

Genentech got a research license to PreEMT technology for refolding and producing proteins

Genentech got an option to obtain a commercial license; terms of the deal were not disclosed (9/7)

Cardiff
ProTides Ltd.*
(UK)

NuCana Ltd.* (UK)

NuCana got exclusive rights to a series of ProTide derivatives of licensed and marketed cancer compounds

Cardiff gets an up-front payment along with potential milestone and royalty payments (9/14)

Cellartis AB*
Ltd.*
(Sweden)

NovaThera (UK)

Deal to use stem cell technology from Cellartis in development of a platform technology for regenerative medicine

The effort is part of a UK government- backed program headed by NovaThera focused on production of clinical-grade stem cells; the companies jointly will pursue commercial applications of resulting technology (8/29)

Cellegy
Pharmaceuticals
Inc.
(OTC BB:CLGY)

ProStrakan Group plc (UK; LSE:PSK)

ProStrakan is acquiring Cellegesic (nitroglycerin ointment) and three testosterone gel products: Fortigel, Tostrex and Tostrelle

ProStrakan already was marketing two of the products in Europe; Cellegy will get $9M in cash in the asset sale (9/27)

CGI
Pharmaceuticals
Inc.*

Genentech Inc. (NYSE:DNA)

Deal to discover, develop and market compounds against an undisclosed target for use in oncology and autoimmune indications

CGI gets $25M up front in the form of license fees and an equity investment; it is eligible to receive milestone and option payments exceeding $500M; Genentech's rights are exclusive except in Europe (10/3)

ChemAxon*
(Hungary)

Evotec AG (Germany; FSE:EVT)

Evotec licensed technology for use in its informatics platform

Evotec licensed Chemaxon's entire product line; terms of the deal were not disclosed (9/5)

Chromos
Molecular
Systems Inc.
(Canada; TSX:CHR)

Y's Therapeutics Inc.*

Chromos will engineer a cell line for use in manufacturing a therapeutic protein candidate from Y's

Chromos will use its ACE System in the effort; terms of the deal were not disclosed (9/21)

CoGenesys
Inc.*

Vegenics Ltd.* (Australia)

Vegenics got worldwide rights to technology in the field of vascular endothelial growth factors

CoGenesys gets an up-front licensing fee, and is entitled to development milestone payments and royalties on any resulting sales (8/21)

CogState Ltd.
(Australia; ASX:
CGS)

Pacific Northwest Biotechnology Inc.*

Pacific Northwest licensed the preclinical drug candidate AT4, which is directed at the angiotensin 4 receptor

CogState is entitled to milestone payments in the deal, and would get a royalty rate of 1% on any resulting sales (8/21)

Crucell NV
(the Netherlands;
CRXL)

ADImmune Corp.* (Taiwan)

ADImmune got rights to use PER.C6 cell line technology to develop a vaccine against Japanese encephalitis virus

Crucell is entitled to a license fee, annual maintenance fees and royalties on any sales; ADImmune would sell resulting products in Taiwan and China (10/11)

Crucell NV
(the Netherlands;
CRXL) and
DSM Biologics
(the Netherlands)

MorphoSys AG (Germany; FSE:MOR)

MorphoSys got rights to use the PER.C6 cell line to produce clinical-grade material for its MOR103 antibody program

It was MorphoSys' second license to the technology; terms of the deal were not disclosed (8/17)

Debiopharm
Group*
(Switzerland)

Salix Pharmaceuticals Ltd. (SLXP)

Salix got exclusive U.S. rights to Sanvar IR, which is in Phase III trials for treating acute esophageal variceal bleeding

Debiopharm is entitled to up to $14M in up- front and regulatory and sales milestone payments, as well as royalties on resulting sales (9/5)

Depomed
Inc.
(DEPO)

Patheon Inc. (Canada; TSX:PTI)

Patheon gained access to Depomed's AcuForm drug delivery technology

Patheon can use the technology in work on pharmaceutical products with its partners; license agreements would be formed for resulting products (8/7)

Diamyd Medical
AB
(Sweden;
SSE:DIAMB)

Neurologix Inc. (OTC BB: NRGX)

Neurologix got a license to to use the glutamic acid decarboxylase 65 gene, a component of its NLX-P101 gene therapy

Diamyd gets a $0.5M license fee, and annual maintenance fees; it also could get certain milestone and royalty payments on the Parkinson's disease product (8/7)

DNAPrint
Genomics Inc.
(OTC BB:DNAG)

NeoCodex Inc.* (Spain)

DNAP will provide DNA sampling for research on the effectiveness of treatments for ovarian cancer

DNAP will work to identify genes of further interest, based on the drug response data provided by NeoCodex; terms of the deal were not disclosed (8/22)

Dyax Corp.
(DYAX)

Trubion Pharmaceuticals Inc. (TRBN)

Dyax will use its phage display libraries to discover compounds that bind to Trubion oncology and inflammation targets

Dyax is entitled to up-front and FTE payments under the nonexclusive deal, as well as potential milestone and royalty payments (9/5)

Dyax Corp. (DYAX)

Serono SA (Switzerland; NYSE:SRA)

Serono got nonexclusive rights to use antibody phage display libraries in antibody discovery and development

Dyax also will perform funded research on certain targets; Dyax gets maintenance and research payments, and is eligible to receive milestone and royalty payments (9/7)

ESBATech AG*
(Switzerland)

Oncalis AG*(Switzerland)

ESBATech spun out its small- molecule inhibitor programs to form Oncalis

Oncalis is being financed by ESBATech's Series A investors; terms of the deal were not disclosed (9/6)

Exiqon A/S*
(Denmark)

Luminex Corp. (LMNX)

Deal to to co-develop and commercialize microRNA products

Products will be based on Luminex's xMAP technology and Exiqon's Locked Nucleic Acid technology; terms were not disclosed (9/19)

GammaCan
International
Inc.
(Israel;
OTC BB:GCAN)

Life Therapeutics Inc.(ASX:LFE)

Deal to develop GammaCan's VitiGam, an intravenous IgG- based immunotherapy for cancer indications

They will share development costs and would share any resulting proceeds in the same proportion (8/22)

Genizon
BioSciences
Inc.*
(Canada)

Genentech Inc. (NYSE:DNA)

Genentech got an exclusive license to Genizon's GeneMap of disease- associated genes in Crohn's disease

The data come from a study of the Quebec Founder Population; Genizon gets an up- front payment and research funding, and could get milestone payments on resulting products (8/8)

GenPat77
Pharmaco-
genetics AG*
(Germany)

Medarex Inc. (MEDX)

Deal to develop fully human antibody products against disease targets provided by GenPat77

Medarex technology will be used to generate the antibodies; they will share development and commercialization responsibilities on resulting products; other terms were not disclosed (8/22)

GPC Biotech
AG
(Germany;
GPCB)

Kinaxo Biotechnologies GmbH* (Germany)

Kinaxo got rights to use GPC's KinaTor technology in fee-for-service activities

The technology is used to identify protein targets; Kinaxo gets exclusive, worldwide rights in that area and the right to sublicense the technology (7/27)

Immunicon
Corp.
(IMMC)

MolMed SpA* (Israel)

Deals under which Immunicon will develop a biomarker for tumor endothelial cells, and analyze cell data from a Phase I trial

The work focuses on MolMed's vascular- targeting compound Aregyr for cancer; terms of the deal were not disclosed (9/28)

Infinity
Pharmaceuticals
Inc.*

MedImmune Inc.(MEDI)

Deal to develop and market small-molecule cancer drugs targeting heat-shock protein 90 and the Hedgehog pathway, programs from Infinity

Infinity gets $70M up front, and up to $430M in late-stage milestone payments; they will share costs and any resulting profits; Infinity retained a U.S. co-promotion option (8/28)

InNexus
Biotechnology
Inc.
(Canada;
CDNX:IXS)

EvoGenix Ltd.
(Australia;
ASX:EGX)

Deal to use InNexus technology with an antiviral antibody being developed by EvoGenix

InNexus will apply its SuperAntibody technology to the antibody; terms of the deal were not disclosed (10/3)

InNexus
Biotechnology
Inc.
(Canada;
CDNX:IXS)

BioInvent International AB (Sweden; SSE:BINV)

Deal to use InNexus technology with a BioInvent therapeutic antibody- targeting cancer

The work will be aimed at a single target; financial terms, and details on future development, were not disclosed (9/27)

InPharma
A/S*
(Norway)

Cytogen Corp. (CYTO)

Cytogen got exclusive North American rights to the oral mucositis product Caphosol

InPharma gets $5M up front and $1M more after six months; it also is entitled to royalties and sales-based milestones; Cytogen also got an option to acquire rights in Europe and Asia (10/11)

Juvantia
Pharma Ltd.*
(Finland)

Santhera Pharmaceuticals AG* (Switzerland)

Deal to develop Juvantia's fipamezole, which was in Phase IIa testing for treating dyskenesia in Parkinson's disease patients

Santhera will conduct further development, and has an option to acquire the product through the purchase of Juvantia; terms of the deal were not disclosed (9/5)

Karo Bio
AB
(Sweden;
SSE:KARO)

Radius*

Radius got worldwide rights, excluding Nordic countries, to a new class of selective androgen-receptor modulators

Milestone payments to Karo for one product could total $17M; it also could get payments for other products and royalties on resulting sales (9/12)

LBS
Technologies
Inc.*

Enzo Biochem Inc. (NYSE:ENZ)

Enzo got rights to patents related to non-PCR-based RNA amplification

The technology provides increased amplification from relatively small RNA samples in gene expression studies; terms of the deal were not disclosed (10/13)

Medinox Inc.*

Logical Therapeutics Inc.*

Logical got exclusive rights to develop the NSAID agent LT-NS001 in North America, Europe and Australia

Medinox gets an up-front payment, and is eligible to receive development and regulatory milestones, as well as royalties on resulting sales (9/5)

Medivir AB
(Sweden;
SSE:MVIRB)

Epiphany Biosciences*

Epiphany got rights to MIV-606, Medivir's Phase II compound against varicella zoster virus and other viruses

Medivir gets equity in Epiphany, and is eligible to receive up to $24.5M in milestone payments, as well as royalties on sales; Medivir retained rights in the Nordic countries (9/8)

MGI Pharma
Inc.
(MOGN)

Medicure Inc. (Canada; TSX:MPH)

Medicure acquired exclusive U.S. rights to Aggrastat, a GP IIb/IIIa inhibitor approved for treating acute coronary syndrome

MGI had acquired the U.S. rights through its acquisition of Guilford Pharmaceuticals Inc., which got the rights from Merck & Co. Inc.; MGI gets $19M in the deal, and Merck gets royalty payments (8/9)

MolecularMD*

Breakthrough Therapeutics*

MolecularMD will monitor disease levels in patients participating in a Phase II trial from Breakthrough

The trial is testing Breakthrough's Ablvax (VAX100) vaccine in patients with resistant chronic myeloid leukemia; terms were not disclosed (8/30)

MondoBiotech
AG*
(Switzerland)

Biogen Idec Inc. (BIIB)

Biogen got rights to develop and market Aviptadil, a Phase II compound for treating pulmonary arterial hypertension

Mondo gets $7.5M up front, and up to $30M in milestone payments, as well as royalties on any resulting sales; also, Biogen would invest $5M in Mondo's initial public offering (9/14)

Multispan
Inc.*

Medarex Inc. (MEDX)

Medarex got rights to HEx GPCR overexpressing cell lines for use as whole-cell immunogens

Specific targets and financial details were not disclosed (10/12)

Newron
Pharmaceuticals
SpA*
(Italy)

Serono SA (Switzerland; NYSE:SRA)

Serono got exclusive rights to the Phase III product safinamide in Parkinson's disease, Alzheimer's disease and other cognitive disorders

Newron is eligible to receive up to $200M in up-front and milestone payments, as well as royalties on resulting sales; Newron also got co-promotion options in Italy and Spain (10/16)

Oncalis AG*
(Switzerland)

ChemDiv Inc.*

Deal to discover and develop compounds that inhibit receptor tyrosine kinase and other cancer- related targets

Each will contribute technologies to the effort; terms of the deal were not disclosed (10/3)

Oncovir Inc.*

Nventa Bio- pharmaceuticals Corp. (TSX:NVN)

Nventa gets rights to use the adjuvant Hiltonol, or Poly-ICLC, which targets the Toll-like receptor 3 pathway

Nventa will use Hiltonol with its HspE7 vaccine for treating human papillomavirus-related diseases; terms of the deal were not disclosed (8/23)

Oxford Gene
Technology
Ltd.*
(UK)

Bio Matrix Research Inc.* (Japan)

Bio Matrix got rights to OGT patents on oligonucleotide microarrays

Bio Matrix got rights to develop, manufacture and market microarrays in Japan; terms of the deal were not disclosed (8/15)

Oxford Gene
Technology
Ltd.*
(UK)

Filgen Inc.* (Japan)

Filgen got rights to OGT patents on oligonucleotide microarrays

Filgen got rights to conduct a microarray service in Japan; terms of the deal were not disclosed (8/15)

PharmaNova
Inc.*

Depomed Inc. (DEPO)

Depomed got rights to patents covering the use of gabapentin for the treatment of menopausal hot flashes

The goal under the exclusive sublicense to patents held by the University of Rochester is to develop a non- hormonal treatment for hot flashes; PharmaNova gets $0.5M up front, and is eligible to receive milestone and royalty payments in that indication (10/18)

Phynova
Group plc
(UK; AIM:PYN)

Botanic Century Co. Ltd.* (China)

They signed a a letter of intent under which Phynova would acquire a 45% stake in Botanic Century, and get an option to increase it to 51%

Phynova would pay about $1M in cash and shares, mostly cash, for the stake; also, Botanic licensed Phynova's PYN18 hepatitis C product for the Chinese market (8/7)

Predix
Pharmaceuticals
Holdings Inc.*

Amgen Inc. (AMGN)

Collaboration to develop oral S1P1 modulators for treating autoimmune diseases; the focus is both existing preclinical compounds from Predix and new compounds

Predix gets $20M up front and up to $287.5M more in milestone payments; it also could get double-digit royalties on resulting sales (7/31)

PrimeCell
Therapeutics
LLC*

Regeneration Technologies Inc. (RTIX)

Deal to pursue orthopedic applications using PrimeCell's germ cell reprogramming technology

They will evaluate the use of stem cells in conjunction with biological implants for improving orthopedic grafts; terms of the deal were not disclosed (8/23)

ProMetic Life
Sciences Inc.

Nabi Bio- pharmaceuticals (NABI)

Nabi got rights to use ProMetic's plasma fractionation technology in the manufacture of its Civacir and Altastaph products

Nabi got exclusive rights to use the technology with those products, and an option (Canada; TSX:PLI) for exclusive North American rights to use it with Nabi-HB (8/29)

ProMetic Life
Sciences Inc.
(Canada; TSX:PLI)

Nabi Bio- pharmaceuticals (NABI)

Nabi got rights to use ProMetic's Mimetic Ligands technology in the manufacturing of certain plasma-derived hyperimmune products

ProMetic is entitled to milestone payments of up to $18M based on BLA filings and approvals, and would get royalties on resulting sales (8/21)

QLT Inc.
(Canada; QLTI)

BioDelivery Sciences International Inc. (BDSI)

BDSI purchased all rights outside the U.S. to BEMA drug delivery technology, for $3M

Prior to the deal, BDSI had licensed BEMA from QLT USA Inc. on a worldwide, exclusive basis; BDSI has an 12-month option to acquire U.S. rights for another $7M (8/3)

Ryogen LLC*

OriGene Technologies Inc.*

OriGene got nonexclusive rights to patents covering the Aminopeptidase P gene

The gene is a marker for a number of dis- eases; terms of the deal were not disclosed (8/15)

Santaris
Pharma A/S*
(Denmark)

Enzon Pharmaceuticals Inc. (ENZN)

Enzon licensed two preclinical candidates, SPC2968 and SPC3042, and six other compounds that will be directed against cancer targets

The RNA antagonists are based on Santaris' locked nucleic acid technology; Enzon gets rights outside Europe; Santaris gets $8M up front, up to $200M in milestone payments and royalties on any resulting sales (7/27)

StemCells
Inc.
(STEM)

Stem Cell Therapeutics Corp. (Canada; CDNX:SSS)

Stem Cell Therapeutics got a license to use technology in the neural stem cell field

StemCells is entitled to up-front and maintenance fees, as well as milestone and royalty payments; it also got rights to use SCT technology in R&D, and would receive royalties on resulting products (8/29)

Synphora
AB*
(Sweden)

Biovitrum AB (Sweden; SSE:BVT)

Biovitrum gained an option to acquire Synphora's Phase I psoriasis candidate JB991, a prostaglandin derivative

Biovitrum will contribute up to SEK5M ($0.68M) to help fund trials through Phase II; it would have an option to acquire the product after Phase IIa trials (10/10)

Syntonix
Pharmaceuticals
Inc.*

Serono SA (Switzerland; NYSE:SRA)

Serono got an option to develop Syntonix's FSH:Fc SynFusion products, focused on a long-acting, inhaled treatment for infertility

Syntonix gets up-front and option fees; if the option is exercised, Syntonix would get additional up-front fees and be eligible for up to $54M in milestone payments, as well as royalties on resulting sales (9/18)

Theragenex
LLC*

Zylera Pharmaceuticals*

Zylera got rights to use Theragenix technologies in development of several products

Terms were not disclosed, but the deal provides for sharing any resulting revenues (8/30)

Tissue
Genesis Inc.*

Bioheart Inc.*

Bioheart got an option to acquire worldwide rights to adipose-derived therapeutic cell technology

Bioheart could gain exclusive rights to use the technology for heart attacks and heart failure; Tissue Genesis would be entitled to up-front and milestone payments (8/8)

Tripos Inc.
(TRPS)

CeNeS Pharmaceuticals plc (UK; AIM:CEN)

They extended deal to develop catechol-O-methyltransferase inhibitors to treat Parkinson's disease

They began the collaboration in 2003; terms of the deal were not disclosed (9/12)

Vaccinex Inc.*

OPi SA* (France)

OPi got worldwide rights to OPR-003, a fully human anti-interleukin-6 antibody

Vaccinex is eligible to receive milestone and royalty payments in the deal; it also has certain co- development options (10/10)

Valentis Inc.
(VLTS)

Inovio Biomedical Corp (AMEX:INO)

Inovio acquired certain DNA delivery and expression assets, including the DNAvax polymer delivery system and GeneSwitch gene regulation technology

It also acquired rights under existing Valentis license agreements; Inovio paid $0.8M, of which $0.3M was offset by an existing debt; Valentis two weeks earlier entered a merger agreement with Urigen NA Inc. (10/17)

XOMA Ltd.
(XOMA)

Attenuon LLC*

XOMA will humanize a monoclonal antibody targeting the urokinase plasminogen activator system

The antibody is being developed for cancer indications; XOMA gets an up-front fee, and could get milestone and royalty payments (10/3)


Notes:

* Private companies are indicated with an asterisk.

# Item occurred before the time frame of this chart but was not included in the previous chart.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange.

No Comments